Patents by Inventor James J. Li

James J. Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200110179
    Abstract: A Lidar system, photonic chip and method of detecting an object. The photonic chip includes a laser and one or more photodetectors. The laser generates a transmitted light beam. The one or more photodetectors are receptive to a reflected light beam that is a reflection of the transmitted light beam from an object and generate an electrical signal as output in response to the reflected light beam signal. An amplifier is configured to amplify a signal related to the reflected light beam to amplify the output signal of the one or more photodetectors. A processor determines a parameter of the object from the amplified output signal.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 9, 2020
    Inventors: Timothy J. Talty, Michael Mulqueen, James Chingwei Li, Ken R. Elliott
  • Publication number: 20200110161
    Abstract: A Lidar system and method of detecting an object is disclosed. The Lidar system includes a photodetector, a spectrum analyzer and a processor. The photodetector generates an electrical signal in response to a reflected light beam received at the photodetector, the reflected light beam being a reflection of a chirp signal from the object. The electrical signal has a bandwidth the same as a bandwidth of the chirp signal. The spectrum analyzer includes a power divider that partitions the electrical signal into a plurality of channels, an analog-to-digital converter that converts the electrical signal within a selected channel from an analog signal to a digital signal, and a comb filter that provides output from the selected channel from the power divider to the analog-to-digital converter. The processor determines a parameter of the object from the digital signal in the selected channel.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 9, 2020
    Inventors: Timothy J. Talty, Michael Mulqueen, James Chingwei Li
  • Patent number: 10519529
    Abstract: An alloy includes, in weight percentage, about 20.0% to about 25.0% chromium, 0% to about 5.0% molybdenum, about 3.0% to about 15.0% cobalt, about 1.5% to about 6.0% niobium, about 1.0% to about 3.0% tantalum, about 1.0% to about 5.0% tungsten, 0% to about 1.0% aluminum, 0% to about 0.05% carbon, 0% to about 0.01% titanium, and the balance nickel and incidental elements and impurities, wherein the alloy includes L12 and D022 precipitates in a compact morphology.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: December 31, 2019
    Assignee: QUESTEK INNOVATIONS LLC
    Inventors: James A. Wright, Weiming Huang, Abhijeet Misra, Jeremy Hoishun Li, Jiadong Gong, Dana J. Frankel
  • Patent number: 10486152
    Abstract: A liquid deposition system comprises a liquid delivery assembly including a dispensing probe having a sidewall including a first end having a liquid port and a second end having a tip, and a flow path opening at the tip and fluidly connected with the liquid port. The system includes a gas injection assembly with a manifold having a gas nozzle, a nozzle opening, and a gas port, the gas nozzle configured to eject a substantially laminar gas stream so that the gas stream travels through a travel path, the tip of the dispensing probe extending into the travel path. The liquid port is fluidly connectable with a liquid source and the gas port is fluidly connectable with a pressurized gas source, so that a liquid micro droplet is formed at the tip. The laminar gas stream separates the micro droplet from the tip and carries it through the travel path.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: November 26, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jay J. Li, Normand P. Desmarais, James E. Rasmussen, Eric Cowden
  • Patent number: 10404293
    Abstract: A method and apparatus for dynamically modifying filter characteristics of a Delta-Sigma modulator to accommodate for Doppler shift. A transceiver in a wireless cellular communication system for adapt to changes in the RF carrier frequency for maintaining signal integrity by applying a pilot tone in calibration to determine a frequency shift response for a bandpass filter. During operation, the system is operative to determine a Doppler shift and to shift the bandpass filter in response.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 3, 2019
    Assignee: GM GLOBAL TECHNOLOGY OPERATIONS LLC
    Inventors: Timothy J. Talty, Cynthia D. Baringer, Mohiuddin Ahmed, Jongchan Kang, Yen-Cheng Kuan, James Chingwei Li, Emilio A. Sovero
  • Publication number: 20190190533
    Abstract: A method and apparatus for utilizing a wideband radio frequency filter to capture an FM frequency band and configuring the characteristics of a delta-sigma modulator in order to processes desired signals within the FM frequency band. Specifically, the system and method are operative to receive a plurality of FM signals within an FM frequency band, filter the frequency band using a wideband filter, modulating the plurality of FM signals using a delta sigma modulator, down converting and processing the desired signals in parallel.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 20, 2019
    Inventors: CYNTHIA D BARINGER, MOHIUDDIN AHMED, JONGCHAN KANG, JAMES CHINGWEI LI, EMILIO A SOVERO, TIMOTHY J TALTY
  • Patent number: 8557841
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: October 15, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino
  • Patent number: 8546394
    Abstract: Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: October 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, James J. Li, Stephen P. O'Connor, Haixia Wang, Lawrence J. Kennedy, Jeffrey A. Robl, Lawrence G. Hamann
  • Patent number: 8541444
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: September 24, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Chenkou Wei, Michael Galella
  • Publication number: 20120252799
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 4, 2012
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino
  • Patent number: 8263630
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are defined herein.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: James J. Li
  • Patent number: 8232291
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: July 31, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino
  • Patent number: 8158648
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z??(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: April 17, 2012
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang
  • Patent number: 8148396
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
  • Patent number: 8119658
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: February 21, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Xinhua Qian, Rajendra P. Deshpande, Laxma R. Kolla, Reginald O. Cann, Chenkou Wei, Michael Galella
  • Publication number: 20110288051
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Application
    Filed: August 3, 2011
    Publication date: November 24, 2011
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Chenkou Wei, Michael Galella
  • Publication number: 20110224199
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino
  • Patent number: 7977353
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: July 12, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino
  • Publication number: 20110077395
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.
    Type: Application
    Filed: December 2, 2010
    Publication date: March 31, 2011
    Inventors: James J. Li, Lawrence G. Hamann, Zheming Ruan, Christopher B. Cooper, Shung C. Wu, Ligaya M. Simpkins, Haixia Wang, Akbar Nayeem, Stanley R. Krystek
  • Patent number: 7910601
    Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1?, R2, R3, R4, Xa, Y, Z and n are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: March 22, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, Jun Li, William R. Ewing, Richard B. Sulsky, James J. Li, Joseph Anthony Tino